|
A Study of MDL 28,574A in HIV-Infected Patients Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A Study of MDL 28,574A in HIV-Infected Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of MDL 28,574A in HIV-Infected Patients Clinical research trials and A Study of MDL 28,574A in HIV-Infected Patients health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A Study of MDL 28,574A in HIV-Infected Patients. A Study of MDL 28,574A in HIV-Infected Patients Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A Study of MDL 28,574A in HIV-Infected Patients clinical trial. Human subjects frequently get the finest healthcare available for their A Study of MDL 28,574A in HIV-Infected Patients condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of MDL 28,574A in HIV-Infected Patients  A Study of MDL 28,574A in HIV-Infected Patients
A Study of MDL 28,574A in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Hoechst Marion Roussel ,
Synopsis: To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (from which MDL 28574A is derived) following both acute and subchronic dosing.
Details: In Part A of the study, patients receive a single oral dose of MDL 28574A on day 1 and are followed through day 7. In Part B, patients receive single daily doses of the drug on days 1 through 14 and are followed through day 21.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV infection. - CD4 count >= 500 cells/mm3. - No evidence of AIDS. - No antiretroviral therapy within 30 days prior to study entry. NOTE: - Presence of lymphadenopathy in two or more extrainguinal sites, at least 1 cm in diameter for 3 or more months, is permitted. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Clinically significant abnormalities on routine hematology (other than CD4 count and Western blot), serum chemistry, and urinalysis. - Abnormal EKG. - Positive stool guaiac. - Abnormal medical history or physical exam including temperature, heart rate, and blood pressure. - Clinically significant organ abnormality or disease. - Positive urine drug screen for illicit drugs. - Inability to comply with study procedures. Concurrent Medication: Excluded: - Routine treatment with nonprescription medications. - Treatment with other medications except with approval of the investigator. Patients with the following prior conditions are excluded: - Prior participation in this trial. - Serious physical or mental illness within 1 year prior to study entry that would confound interpretation of data. Prior Medication: Excluded: - Antiretroviral therapy within 30 days prior to study entry. - Known medications that alter renal, hepatic, or hematologic/immunologic function (such as barbiturates, phenothiazines, cimetidine, and immunomodulators) within 14 days prior to study entry. - Routine treatment with nonprescription medications within 3 days prior to study entry. History of alcohol or drug abuse within the past year.
Total Enrollment:
Location and Contact Information:
Saint Francis Mem Hosp
San Francisco, California, 94109
United States
Additional Information:
Study ID Numbers: 221A; NDPR0002
Study Start Date:
Record last reviewed: May 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002329
Other Hiv Infections Studies:
1. Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
2. Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
3. A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
4. Garlic in hyperlipidemia caused by HAART
5. The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients with AIDS or AIDS Related Complex
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Study of MDL 28,574A in HIV-Infected Patients
|
|
|
|
|
|
|
|
